Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Angiotensin Receptor 2 Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the Angiotensin Receptor 2 in transfected HEK293 cells
AT2 (non-phospho-Angiotensin Receptor 2 Antibody)
The non-phospho-AT2 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human Angiotensin Receptor 2 (AT2). It can be used to detect total AT2 receptors in Western blots independent of phosphorylation....
375.00 € *
Details

The angiotensin II type 2 receptor (AT₂R) is a class A G protein–coupled receptor (GPCR) that binds angiotensin II (Ang II) with high affinity but mediates signaling actions that often oppose those of the angiotensin II type 1 receptor (AT₁R). Unlike AT₁R, which couples to Gq/11 and promotes vasoconstriction and proliferation, AT₂R primarily signals through Gi/o proteins, nitric oxide (NO)–cGMP pathways, and protein phosphatases such as SHP-1 and PP2A, leading to vasodilation, anti-proliferative, anti-inflammatory, and neuroprotective effects. AT₂R is highly expressed during fetal development, especially in the brain, kidney, and vasculature, but its expression declines after birth, persisting at lower levels in adult tissues including the heart, adrenal gland, brain, and reproductive organs. Under pathological conditions such as tissue injury, inflammation, and cardiovascular disease, AT₂R expression is often upregulated, suggesting a role in tissue repair and remodeling. Pharmacologically, selective AT₂R agonists such as Compound 21 (C21) have demonstrated neuroprotective, antifibrotic, and vasodilatory effects in preclinical and early clinical studies. AT₂R activation can also counteract AT₁R-mediated oxidative stress and fibrosis, contributing to cardiovascular and renal protection. Emerging evidence supports AT₂R involvement in pain modulation and metabolic regulation, expanding its therapeutic potential beyond the renin–angiotensin system. Overall, the AT₂ receptor is recognized as a protective and restorative component of angiotensin signaling, offering a promising pharmacological target for cardiovascular, renal, and neurodegenerative diseases. For more information on AT2 pharmacology please refer to the IUPHAR database. For further reading refer to:

de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. PMID: 10977869.

Alexander W, Bernstein KE, Catt KJ, de Gasparo M, Dhanachandra Singh K, Eguchi S, Escher E, Goodfriend TL, Horiuchi M, Hunyady L, Husain A, Inagami T, Karnik S, Kemp J, Thomas WG, Timmermans PBMWM, Tirupula K, Unal H, Unger T, Vanderheyden P. Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

The angiotensin II type 2 receptor (AT₂R) is a class A G protein–coupled receptor (GPCR) that binds angiotensin II (Ang II) with high affinity but mediates signaling actions that often oppose... read more »
Close window
Angiotensin Receptor 2 Antibodies

The angiotensin II type 2 receptor (AT₂R) is a class A G protein–coupled receptor (GPCR) that binds angiotensin II (Ang II) with high affinity but mediates signaling actions that often oppose those of the angiotensin II type 1 receptor (AT₁R). Unlike AT₁R, which couples to Gq/11 and promotes vasoconstriction and proliferation, AT₂R primarily signals through Gi/o proteins, nitric oxide (NO)–cGMP pathways, and protein phosphatases such as SHP-1 and PP2A, leading to vasodilation, anti-proliferative, anti-inflammatory, and neuroprotective effects. AT₂R is highly expressed during fetal development, especially in the brain, kidney, and vasculature, but its expression declines after birth, persisting at lower levels in adult tissues including the heart, adrenal gland, brain, and reproductive organs. Under pathological conditions such as tissue injury, inflammation, and cardiovascular disease, AT₂R expression is often upregulated, suggesting a role in tissue repair and remodeling. Pharmacologically, selective AT₂R agonists such as Compound 21 (C21) have demonstrated neuroprotective, antifibrotic, and vasodilatory effects in preclinical and early clinical studies. AT₂R activation can also counteract AT₁R-mediated oxidative stress and fibrosis, contributing to cardiovascular and renal protection. Emerging evidence supports AT₂R involvement in pain modulation and metabolic regulation, expanding its therapeutic potential beyond the renin–angiotensin system. Overall, the AT₂ receptor is recognized as a protective and restorative component of angiotensin signaling, offering a promising pharmacological target for cardiovascular, renal, and neurodegenerative diseases. For more information on AT2 pharmacology please refer to the IUPHAR database. For further reading refer to:

de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. PMID: 10977869.

Alexander W, Bernstein KE, Catt KJ, de Gasparo M, Dhanachandra Singh K, Eguchi S, Escher E, Goodfriend TL, Horiuchi M, Hunyady L, Husain A, Inagami T, Karnik S, Kemp J, Thomas WG, Timmermans PBMWM, Tirupula K, Unal H, Unger T, Vanderheyden P. Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Recently viewed